骨化三醇联合常规治疗对慢性肾脏病患者肾功能、炎性因子及钙磷代谢的影响

目的:探讨骨化三醇联合常规治疗对慢性肾脏病(CKD)患者肾功能、炎性因子及钙磷代谢的影响。方法:选取2016年2月~2019年2月我院收治的CKD患者103例,根据随机数字表法将患者分为对照组(n=51)和研究组(n=52),其中对照组给予常规治疗,研究组在对照组基础上联合骨化三醇治疗,比较两组患者肾功能指标、炎性因子及钙磷代谢水平,记录两组治疗期间不良反应发生情况。结果:两组患者治疗3个月后尿素氮(BUN)、血肌酐(SCr)、24 h尿蛋白定量均下降,且研究组低于对照组(P<0.05)。两组患者治疗3个月后血钙水平升高,血磷水平降低(P<0.05);研究组治疗3个月后血磷水平低于对照组,血钙水平高于对照组(P<0.05)。两组患者治疗3个月后血清白介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平均降低,且研究组低于对照组(P<0.05)。两组均未见明显不良反应。结论:骨化三醇联合常规治疗可有效改善CKD患者肾功能,提高血钙水平,降低炎性因子、血磷水平,且用药安全性较好,具有一定的临床应用价值。

Effects of Calcitriol Combined with Conventional Therapy on Renal Function, Inflammatory Factors and Calcium and Phosphorus Metabolism in Patients with Chronic Kidney Disease

Objective: To investigate the effects of calcitriol combined with conventional therapy on renal function, inflammatory factors and calcium and phosphorus metabolism in patients with chronic kidney disease(CKD). Methods: 103 patients with CKD who were admitted to our Hospital from February 2016 to February 2019 were selected, and they were divided into control group(n=51) and study group(n=52) according to random number table method. The control group was given routine treatment, and the study group was treated with calcitriol on the basis of the control group. The renal function indicators, inflammatory factors and calcium and phosphorus metabolism levels change were compared between the two groups, and the occurrence of adverse reactions during treatment in two groups were recorded. Results: 3 months after treatment, urea nitrogen(BUN), serum creatinine(SCr) and 24 h urinary protein in the two groups decreased, and those in the study group were lower than those in the control group(P<0.05). 3 months after treatment, blood calcium level increased, and blood phosphorus level decreased in the two groups(P<0.05). 3 months after treatment, blood phosphorus level was lower than that in the control group, blood calcium level in the study group was higher than that in the control group(P<0.05). The levels of serum interleukin-6(IL-6), high-sensitivity C-reactive protein(hs-CRP) and tumor necrosis factor-α(TNF-α) were decreased in the two groups at 3 months after treatment, and those in the study group were lower than those in the control group(P<0.05). There were no obvious adverse reactions in the two groups. Conclusion: Calcitriol combined with conventional therapy can effectively improve renal function, increase blood calcium level, reduce inflammatory factors and blood phosphorus levels in CKD patients, and it has good safety of medication, which has certain clinical application value.